



Health Technology Assessment (HTA) & integration in Pharmacoepidemiology

Luis Prieto

Pharmacovigilance & Risk Management

ENCePP Plenary, London, 03.05.2012




What is HTA?

- **HTA** is a field of scientific research to inform policy and clinical decision-making around the introduction and diffusion of health technologies.
- Health technologies include pharmaceuticals, devices, diagnostics and treatments, and other clinical, public health, and organizational interventions.
- HTA is a multidisciplinary field that addresses the health impacts of technology, considering its specific healthcare context as well as available alternatives. Contextual factors addressed by HTA include economic, organizational, social, and ethical impacts. The scope and methods of HTA may be adapted to respond to the policy needs of a particular health system.
- In health systems throughout the world, HTA plays an essential role in supporting decision-making about access to technology, its diffusion, and innovation.

Source: http://www.htai.org



The HTA process



Health Technology Agencies





Agencies for HTA in Europe (i)



Source: http://www.inahta.net/

- Regional
- National






Agencies for HTA in Europe (ii)



Source: http://www.inahta.net/







Agencies for HTA in Europe (iii)




Source: http://www.inahta.net/

- Regional
- National
- International



Agencies for HTA in Europe (iv)







EUnetHTA tools

Developed within the EUnetHTA context and available for EUnetHTA partners.

- <u>EUnetHTA Planned and Ongoing Projects (POP)</u>
 <u>Database</u>
- HTA Core Model®
- <u>EUnetHTA News aggregator</u>
- EVIDENT



EUnetHTA's EVIDENT Database

The Evidence database on new technologies (EVIDENT Database) allows to share information on promising health technologies: remaining evidence gaps, recommendation or request for further research, and additional data collection in development.



Domains of EUnetHTA's HTA Core Model

The HTA Core Model employs a multidisciplinary view of HTA. Any technology that is being assessed is considered through domains, each of which provides a wide framework for the analysis:

- 1. Health problem and current use of technology
- 2. Description and technical characteristics of technology
- 3. Clinical effectiveness
- 4. Safety
- 5. Costs and economic evaluation
- 6. Ethical analysis
- 7. Organisational aspects
- 8. Social aspects
- 9. Legal analysis




Framework for ENCePP and EUnetHTA collaboration

EUnetHTA Joint Action (JA) 2010-12

- JA WP7 New Technologies:
 - Deliverable 4: Operational web-based toolkit including database containing information on evidence generation on new technologies (EVIDENT)
- JA WP4 Core HTA
 - "Safety" domain definition, and practical application



Bridging the gap



Four opportunities for collaboration


- 1. EPAR project
- 2. Continue collaboration between ENCePP studies database and EUnetHTA WP7 EVIDENT (focus in 2012):
 - -Linking the databases
 - -Common searches
- 3. WP4 Core HTA

"Safety" domain definition, and practical application. An HTA to include an assessment of the adverse events resulting from the use of a health technology both to benefit individual patients and to inform policy makers. Definitions and terminology of safety used in HTA may need standardisation. Access to ADR data.

4. Relative effectiveness



Relative effectiveness







Opportunities for collaboration & ENCePP

- Methodological considerations at interface of pharmacoepidemiology and HTA
- Research access to insurance / healthcare delivery data
- ENCePP as service provider to HTA



"I look forward to hearing your proposals for what you can contribute to the regulation-HTA bridge"

Guido Rasi

ENCePP Plenary Nov 2011



Proposed actions

- Establish an ENCePP HTA Task-Force to explore opportunities for collaboration
 - Please send your expressions of interest to take part on this initiative to the Secretariat by the 18th of May
- Launch of an ENCePP HTA Survey aimed at collecting information on the experience the centres might have on this matter
 - To be sent to you in the coming days

